A Phase I, Open-Label, Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Ipilimumab (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb; Medarex
- 25 Jan 2018 New trial record